Bahl & Gaynor Inc. Reduces Position in Kenvue Inc. $KVUE

Bahl & Gaynor Inc. trimmed its holdings in Kenvue Inc. (NYSE:KVUE) by 6.7% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 167,710 shares of the company’s stock after selling 12,019 shares during the quarter. Bahl & Gaynor Inc.’s holdings in Kenvue were worth $3,510,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Truvestments Capital LLC bought a new stake in shares of Kenvue in the first quarter worth approximately $37,000. Trust Co. of Vermont lifted its position in Kenvue by 266.8% during the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after purchasing an additional 1,150 shares during the period. Clal Insurance Enterprises Holdings Ltd boosted its holdings in Kenvue by 378.5% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after purchasing an additional 1,287 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich boosted its holdings in Kenvue by 120.6% in the first quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company’s stock worth $41,000 after purchasing an additional 929 shares during the last quarter. Finally, Ransom Advisory Ltd bought a new stake in Kenvue in the 1st quarter worth approximately $56,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

KVUE has been the topic of several research analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Kenvue in a report on Tuesday, October 14th. Rothschild Redb raised Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, September 26th. Deutsche Bank Aktiengesellschaft set a $18.00 target price on Kenvue in a report on Friday, October 24th. Evercore ISI set a $18.00 price target on shares of Kenvue in a research report on Tuesday, October 28th. Finally, UBS Group lowered their price objective on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $20.23.

Kenvue Price Performance

Shares of Kenvue stock opened at $16.63 on Friday. The stock’s 50-day simple moving average is $16.17 and its 200-day simple moving average is $19.80. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17. The company has a market capitalization of $31.86 billion, a price-to-earnings ratio of 22.17, a PEG ratio of 2.31 and a beta of 0.71. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last released its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The firm had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.83 billion. During the same quarter last year, the business posted $0.28 earnings per share. The firm’s revenue was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th will be paid a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 5.0%. The ex-dividend date of this dividend is Wednesday, November 12th. Kenvue’s dividend payout ratio (DPR) is presently 110.67%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.